MedTrace Logo

Estradiol, Progesterone and Endometrial Thickness in Frozen Euploid Embryo Transfer

NCT03395665 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 299

Last updated 2018-02-28

No results posted yet for this study

Summary

The development and improvement in Preimplantation genetic diagnosis/screening (PGS) in association with the efficacy and security of vitrification and trophectoderm biopsy, more efficient stimulation schemes and laboratory improvements in culture and embryo selection have contributed to high success of the assisted reproductive technologies(ART). Transferring an euploid embryo avoids one of the main reasons of miscarriage and implantation failure ( Rubio et al, 22016) and overcomes one of the most important confounding factors. Usually, the transfer of euploid embryos is performed under standard hormone replacement therapy (HRT) and are referred to as FET-PGS cycles( Frozen embryo transfer). The study of FET-PGS cycles with the transfer of a single euploid blastocyst is the best model for evaluation of the impact of the endometrial preparation . Among factors influencing FET outcomes, patient's age, endometrial preparation, endometrium thickness, endometrial pattern, number and quality of embryos transferred , difficulty at ET, recently P4 have received more attention .

The importance of Progesterone (P4) in embryo implantation has been widely studied. P4 plays an important role in endometrial gland formation, embryonic implantation and pregnancy maintenance, both in natural and artificial cycles.

Conditions

  • Infertility
  • Preimplantation Genetic Diagnosis/Screening
  • Miscarriage

Interventions

OTHER

Estradiol level

Estradiol level measured at previous day of embryo transfer procedure

OTHER

Progesterone level

Progesterone level measured at previous day of embryo transfer procedure

OTHER

Endometrial thickness

Endometrial thickness measured at previous day of embryo transfer procedure

Sponsors & Collaborators

  • Fundacion Dexeus

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
43 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2017-12-31
Completion
2018-01-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03395665 on ClinicalTrials.gov